NCT03943212

Brief Summary

A majority of patients with end-stage renal disease (ESRD) on in-center hemodialysis (HD) require several hours to recover from fatigue after an HD session. Evidence for practical interventions to improve this recovery time from conventional in-center HD is lacking. This study investigates the effects of reducing HD blood flow rates on patients' self-reported post-dialysis fatigue.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
102

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Sep 2017

Shorter than P25 for not_applicable

Geographic Reach
1 country

18 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 26, 2017

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 24, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 24, 2018

Completed
12 months until next milestone

First Submitted

Initial submission to the registry

May 7, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 9, 2019

Completed
Last Updated

May 9, 2019

Status Verified

May 1, 2019

Enrollment Period

8 months

First QC Date

May 7, 2019

Last Update Submit

May 7, 2019

Conditions

Keywords

Patient-Reported OutcomesPost-dialysis FatigueDialysis Recovery Time

Outcome Measures

Primary Outcomes (1)

  • Dialysis Recovery Time

    Mean difference in change in Dialysis Recovery Time between the Blood Flow Rate Reduction group and the Control group. Dialysis recovery time is measured by asking the question, "How long did it take you to recover from dialysis?"

    4 weeks

Secondary Outcomes (1)

  • London Evaluation of Illness

    4 weeks

Study Arms (2)

Blood Flow Rate Reduction

EXPERIMENTAL

Participants will have their hemodialysis blood flow rate reduced on their regular schedule.

Other: Blood Flow Rate Reduction

Control

SHAM COMPARATOR

Participants will continue to receive regularly-scheduled hemodialysis without any changes to the prescription.

Other: Control

Interventions

Hemodialysis blood flow rate will be reduced by 100 mL/min, or to a minimum of 300 mL/min, whichever is higher. Patients will be surveyed regarding their dialysis recovery time and other symptoms weekly.

Blood Flow Rate Reduction
ControlOTHER

No changes will be made to the dialysis prescription. Patients will be surveyed regarding their dialysis recovery time and other symptoms weekly.

Control

Eligibility Criteria

Age18 Years - 89 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • A diagnosis of end-stage renal disease undergoing hemodialysis in the San Francisco Bay Area at approved Satellite Healthcare dialysis centers.
  • Dialysis recovery time of 6 or more hours.
  • Not hospitalized in the 7 days prior to study

You may not qualify if:

  • Currently or possibly pregnant, currently trying to become pregnant
  • Inability to provide informed consent
  • Inability to provide responses to survey questions
  • Planned move away from the current hemodialysis center within the study period
  • Undergoing nocturnal hemodialysis, planned changed to nocturnal or peritoneal dialysis, planned kidney transplant within the study period, or other major planned change in hemodialysis prescription
  • Primary nephrologist objection to enrollment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (18)

Satellite Dialysis Capitola

Capitola, California, 95010, United States

Location

Satellite Dialysis Daly City

Daly City, California, 94014, United States

Location

Satellite Dialysis Gilroy

Gilroy, California, 95020, United States

Location

Satellite Dialysis Menlo Park

Menlo Park, California, 94025, United States

Location

Satellite Dialysis Milpitas

Milpitas, California, 95035, United States

Location

Satellite Dialysis Mountain View

Mountain View, California, 94040, United States

Location

Satellite Dialysis East San Jose

San Jose, California, 95116, United States

Location

Satellite Dialysis Santa Teresa

San Jose, California, 95119, United States

Location

Satellite Dialysis Silver Creek

San Jose, California, 95121, United States

Location

Satellite Dialysis South San Jose

San Jose, California, 95123, United States

Location

Satellite Dialysis White Road

San Jose, California, 95127, United States

Location

Satellite Dialysis Bascom

San Jose, California, 95128, United States

Location

Satellite Dialysis Stevens Creek

San Jose, California, 95129, United States

Location

Satellite Dialysis West San Leandro

San Leandro, California, 94577, United States

Location

Satellite Dialysis San Mateo

San Mateo, California, 94403, United States

Location

Satellite Dialysis South San Francisco

South San Francisco, California, 94080, United States

Location

Satellite Dialysis Sunnyvale

Sunnyvale, California, 94086, United States

Location

Satellite Dialysis Watsonville

Watsonville, California, 95076, United States

Location

MeSH Terms

Conditions

Kidney Failure, ChronicFatigue

Condition Hierarchy (Ancestors)

Renal Insufficiency, ChronicRenal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsSigns and Symptoms

Study Officials

  • Brigitte Schiller, MD

    Chief Medical Officer

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Parallel-Group, Randomized Controlled Trial
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Chief Medical Officer

Study Record Dates

First Submitted

May 7, 2019

First Posted

May 9, 2019

Study Start

September 26, 2017

Primary Completion

May 24, 2018

Study Completion

May 24, 2018

Last Updated

May 9, 2019

Record last verified: 2019-05

Data Sharing

IPD Sharing
Will not share

Locations